| Factor Information | |
|---|---|
| Data ID | 2694 |
| Factor | SaO2, % |
| Description | In the ASD group, arterial oxygen saturation improved significantly from 90.98% ± 5.04% to 93.26% ± 2.95% (P = 0.019). |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | The potential effect of sildenafil on pulmonary arterial hypertension related to CHD may be associated with shunt location. |
| p Value | 0.019 |
| Conclusion | In the ASD group, arterial oxygen saturation improved significantly from 90.98% ± 5.04% to 93.26% ± 2.95% (P = 0.019). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 484 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/VSD/PDA |
| Reference | |
|---|---|
| PMID | 21678455 |
| Year | 2011 |
| Title | The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease |
| Sample | ||
|---|---|---|
| Population | adults | |
| Source | 12-week, prospective, open label, multicenter trial | |
| Region | Beijing, China | |
| Method | 12-week, prospective, open label, multicenter trial | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | ASD (12 Weeks)(Treatment) | ASD (Baseline)(Control) |
| Number | 15 | 15 |
| Age | 32.20 ± 6.32 years | 32.20 ± 6.32 years |
| Gender (Male: Female) | 0:15 | 0:15 |
| Marker Level | 93.26 ± 2.95 % | 90.98 ± 5.04 % |
